Three years after AbbVie stood at the edge of a major patent cliff with the loss of exclusivity for immunology ...

Oruka Therapeutics said on Monday that interim results showed its experimental drug helped clear psoriasis within 16 weeks, ​meeting the main goal of a mid-stage ‌study and sending its shares up 20.3% ...

Phase 1 studies showed that one shot of ORKA-001 lasted long enough to allow dosing twice-a-year—or even once-a-year.

Johnson & Johnson’s immunology drug Tremfya is looking to challenge AbbVie’s dominance in 2026, securing the top spot as the biggest TV drug ad spender in March. J&J spent $50.3 million on TV ads for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

AbbVie on Wednesday reported better-than-expected ⁠quarterly ⁠revenue and profit, fueled ⁠by demand for newer immunology ...

Osteoarthritis affects around 600 million people globally. It causes pain, stiffness and reduced joint function – most commonly in the knees, hands and hips. There’s currently no cure for ...

Johnson & Johnson beat first-quarter earnings expectations on Tuesday and raised its full-year forecast, as strong demand for cancer drug Darzalex and psoriasis treatment Tremfya more than offset a ...

The nation's health secretary reportedly plans to remove restrictions on selling peptide injections — making them available to more people. Dr. Abby Waldman from Mass. General Brigham tells you what ...

Los Angeles Lakers star Luka Doncic seeks to do whatever necessary to speed up his injury rehab. Doncic, 27, has reportedly jetted off to Spain in hopes of pursuing specialized treatment for a Grade 2 ...

Johnson & Johnson (J&J) has reported new findings from the QUASAR long-term extension study of Tremfya (guselkumab) for ulcerative colitis (UC). The results highlighted that the dual-acting monoclonal ...

With funding from ARPA-H, three teams of researchers have regrown bone and cartilage, even entire knees, in animal studies. Human trials are not far off. By Gina Kolata Three years ago, a little-known ...